Relapsed/refractory (R/R) mature T and natural killer (NK)-cell lymphomas (TNKL) are aggressive blood cancers often resistant to frontline therapies. A team of Mass General Brigham researchers found ...

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has granted 2,135,000 incentive ...

The world of oncology is evolving rapidly, with breakthrough technologies transforming the way cancer is treated and managed.

While chemotherapy, radiation and surgeries are common for most cancer treatments, immunotherapy is continuing to allow some ...

As former NCI Director W. Kimryn Rathmell, MD, PhD, MMHC, embarks on the next stage of her career as CEO of the James Cancer ...

The ability of mutations to cause cancer depends on how fast they force cells to divide, Sinai Health researchers have found.

Non-coding RNAs (ncRNAs), once considered the 'dark matter' of the genome, have now emerged as pivotal regulators in cancer ...

Natural killer cells aren't just mindless defenders — a special type, adaptive NK cells, remember their enemies and come back ...

HonorHealth Research Institute recently treated the first patient in a 50-site international clinical trial that will test a ...